Protego Biopharma announced it raised $51 Million in an initial filing from an offering of $51 Million

Company

Location

About

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.